Tscan Therapeutics is trading 5.4% down in pre-market at $0.36 after announcing on September 2, 2026, that it would pause further enrollment in the Phase 3 ALLOHA-2 study because of insufficient capital.
- The company is shifting resources toward preclinical solid-tumor programs, eliminating internal manufacturing, and cutting approximately 75% of its workforce.
- The restructuring is expected to generate $55 million in savings through 2027.
- Wedbush downgraded the company to Neutral and cut its price target to $1.00 from $5.00.